Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking phenytoin and levetiracetam: a case report

Journal of Medical Case Reports

Jason Steven Fromm¹  David Jeffrey Hall² 

[1] Department of Medicine, University of Florida College of Medicine, 1600 SW Archer Road, PO Box 100277, Gainesville, FL, 32610-0277, USA;College of Medicine, University of Florida College of Medicine, 1600 SW Archer Road, PO Box 100277, Gainesville, FL, 32610-0277, USA

关键词: Rash;    Phenytoin;    Levetiracetam;    Hypersensitivity reaction;    Hepatitis;    DRESS syndrome;    Anti-epileptic;    Allergy;   

Others  :  1195159
DOI  :  10.1186/1752-1947-7-2

 received in 2012-08-17, accepted in 2012-11-22,  发布年份 2013

【 摘 要 】

Introduction

Drug reaction with eosinophilia and systemic symptoms syndrome is a potentially life-threatening hypersensitivity reaction with rash, fever, and internal organ involvement, often hepatitis, occurring most commonly two to eight weeks after initiation of a medication. The present case is an example of severe and potentially life-threatening hepatitis as a manifestation of drug reaction with eosinophilia and systemic symptoms syndrome.

Case presentation

We report a case of anti-epileptic-induced drug reaction with eosinophilia and systemic symptoms syndrome in an 18-year-old African-American man who presented with a five-day history of rash, periorbital and upper extremity edema, hepatitis and fever. Laboratory findings revealed an atypical lymphocytosis, eosinophilia, and elevated serum transaminases. No drug allergies were reported at the time of presentation, but phenytoin and levetiracetam therapy had been initiated five weeks prior to hospital admission for new-onset seizures. Both medications were discontinued on hospital admission, and after three days of high-dose corticosteroid therapy the patient experienced resolution of both his symptoms and laboratory markers of inflammation.

Conclusion

Given the significant mortality attributed to drug reaction with eosinophilia and systemic symptoms syndrome, medical personnel should be aware of the potential for this severe hypersensitivity reaction and should ensure close follow-up and offer anticipatory guidance when beginning any new medication, particularly anti-epileptic therapy. Early recognition of drug reaction with eosinophilia and systemic symptoms syndrome and initiation of appropriate therapy are imperative in limiting morbidity.

【 授权许可】

   
2013 Hall and Fromm; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bocquet H, Bagot M, Roujeau JC: Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996, 15:250-257.
• [2]Shiohara T, Iijima M, Ikezawa Z, Hashimoto K: The diagnosis of DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Response Br J Dermatol 2007, 156:1045-1092.
• [3]Vauthey L, Uckay I, Abrassart S, Bernard L, Assal M, Ferry T, Djordjevic M, Roussos C, Vaudaux P: Vancomycin-induced DRESS syndrome in a female patient. Pharmacology 2008, 82:138-141.
• [4]Savard S, Desmeules S, Riopel J, Agharazii M: Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Am J Kidney Dis 2009, 54:e17-e20.
• [5]Velema MS, Voerman HJ: DRESS syndrome caused by nitrofurantoin. Neth J Med 2009, 67:147-149.
• [6]Criado PR, Criado RF, Jde Avancini M, Santi CG: Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts. An Bras Dermatol 2012, 87(3):435-449.
• [7]Gómez-Zorrilla S, Ferraz AV, Pedrós C, Lemus M, Peña C: Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome. Ann Pharmacother 2012, 46(7–8):e20.
• [8]Tennis P, Stem RS: Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997, 49:542-546.
• [9]Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA: Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics 2001, 108(2):485-492.
• [10]Ben m’rad M, Leclerc-Mercier S, Blanche P, Franck N, Rozenberg F, Fulla Y, Guesmi M, Rollot F, Dehoux M, Guillevin L, Moachon L: Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009, 88:131-140.
• [11]Chaiken BH, Goldberg BI, Segal JP: Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950, 242(23):897-898.
• [12]Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC: The DRESS syndrome: a literature overview. Am J Med 2011, 124(7):588-597.
• [13]Frieling G, Jessup C, Mihm M: Drug rash with eosinophilia and systemic symptoms. In Diagnostic Pathology: Non-neoplastic Dermatopathology. 1st edition. Edited by Hall BJ, Hall JC, Cockerell CJ. Salt Lake City, UT: Amirsys Publishing, Inc; 2012:10-11.
• [14]Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC: Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007, 156(3):609-611.
• [15]Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T: Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998, 134:1108-1112.
• [16]Kano Y, Inaoka M, Shiohara T: Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004, 140:183-188.
• [17]Descamps V, Ben-Saïd B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, Guinnepain MT, Mathelier-Fusade P, Assier H, Milpied B, Modiano P, Lebrun-Vignes B, Barbaud A, groupe Toxidermies de la Société française de dermatologie: Management of drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 2010, 137:703-708.